Understand the source comparison
IGF-1 LR3 vs Native IGF-1: Functional Comparison
The decision of whether IGF-1 LR3 is worth it becomes clearer when comparing the operational characteristics side by side across the parameters that matter most for research design. Circulating Half-Life 10–15 minutes (rapid IGFBP binding) 20–30 hours (IGFBP-r
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The decision of whether IGF-1 LR3 is worth it becomes clearer when comparing the operational characteristics side by side across the parameters that matter most for research design.
- Circulating Half-Life
- 10–15 minutes (rapid IGFBP binding)
- 20–30 hours (IGFBP-resistant)
- LR3 provides 100× longer bioactive window per dose
- Dosing Frequency (typical)
- 3–4× daily for sustained effects
- 1× daily or every other day
- LR3 reduces administration burden by 70–85%
- IGFBP Binding Affinity
- High (99% bound in circulation)
- ~1% of native IGF-1 (remains free)
- LR3 maintains bioavailable free fraction 100× longer
- Cost per Milligram
- $90–140
- $180–240
- Higher unit cost offset by lower total consumption
- Total Peptide per 12-Week Study
- 25–40 mg
- 8–10 mg
- LR3 uses 60–75% less total peptide mass
- Protocol Complexity
- High (250+ injections, multi-daily dosing)
- Low (84–168 total doses)
- LR3 simplifies logistics and reduces handling errors